Loading…
Intensity Therapeutics, Inc. is projected to rise to $4.70 by 2027, a +10% move from its current price of $4.26. INTS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.14 | $4.26 | $4.38 | -0.05% |
| Aug 6 | $4.09 | $4.26 | $4.42 | -0.11% |
| Aug 7 | $4.06 | $4.25 | $4.46 | -0.16% |
| Aug 8 | $4.02 | $4.25 | $4.49 | -0.21% |
| Aug 9 | $4.00 | $4.25 | $4.52 | -0.26% |
| Aug 10 | $3.97 | $4.25 | $4.54 | -0.32% |
| Aug 11 | $3.95 | $4.24 | $4.56 | -0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.95 | $4.24 | $4.56 | -0.37% |
| Week 2 | $3.82 | $4.23 | $4.69 | -0.74% |
| Week 3 | $3.72 | $4.21 | $4.78 | -1.10% |
| Week 4 | $3.63 | $4.20 | $4.85 | -1.47% |
| Week 5 | $3.56 | $4.18 | $4.92 | -1.83% |
| Week 6 | $3.49 | $4.17 | $4.98 | -2.20% |
| Week 7 | $3.43 | $4.15 | $5.03 | -2.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Intensity Therapeutics, Inc. is a healthcare company described as a late‑stage clinical biotechnology entity. It focuses on treatments for the regional and systemic nature of cancer relapse and metastasis in the United States. The company trades under the symbol INTS and operates in the healthcare sector.
INTS is a small-cap biotechnology stock with a current price of $4.05 and a market capitalization of $10.95M, ranking 4786. The stock sits in a high-volatility space typical of late-stage clinical entities with limited near-term visibility. The 30-day technical picture shows a bearish bias, with a current price below some key moving averages and a defined support and resistance band.
A major floor 21.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.0% below — buyers have tended to step in here.
The nearest ceiling, 15.5% above — a clean break opens room to run.
A major ceiling 49.8% above — clearing it would confirm fresh momentum.
Key INTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.33 | Sell | $4.27 | Sell |
| MA 10 | $4.40 | Sell | $4.38 | Sell |
| MA 20 | $4.61 | Sell | $4.43 | Sell |
| MA 50 | $4.30 | Sell | $4.56 | Sell |
| MA 100 | $4.96 | Sell | $5.30 | Sell |
| MA 200 | $7.37 | Sell | $8.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.02 | Neutral |
| Stoch RSI (14) | 13.42 | Buy |
| CCI (20) | -135.85 | Sell |
| Williams %R (14) | -88.24 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -14.26 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 11.76 | Buy |
| TRIX (15) | 0.21 | Buy |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 34.39 | Neutral |
| Momentum (10) | -0.60 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 4.17 | Buy |
| ADX (14) | 20.87 | Sell |
| ATR (14) | 0.11 | Info |
The near-term technical picture is bearish, with RSI14 at 40. The SMA50 is $4.31 and the SMA200 is $7.39, indicating the price is trading below the shorter-term moving average and well below the longer-term trend line. The 30-day price range runs from $3.38 to $4.86, with support at $3.67 and resistance at $4.92.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.62 | $4.26 | $4.90 | 0% | Neutral | |
| $3.75 | $4.70 | $6.23 | +10% | Neutral | |
| $3.93 | $5.08 | $6.99 | +19% | Neutral | |
| $3.76 | $4.97 | $7.05 | +17% | Neutral | |
| $3.51 | $4.74 | $6.89 | +11% | Neutral | |
| $3.37 | $4.63 | $6.88 | +9% | Neutral | |
| $3.54 | $4.96 | $7.51 | +16% | Neutral | |
| $3.85 | $5.47 | $8.42 | +28% | Bullish | |
| $4.21 | $6.08 | $9.52 | +43% | Bullish | |
| $4.29 | $6.29 | $9.99 | +48% | Bullish | |
| $5.44 | $8.52 | $14.41 | +100% | Bullish | |
| $6.21 | $10.94 | $20.26 | +157% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.62 | $4.26 | $5.03 | +0.00% |
| September 2026 | $3.42 | $4.04 | $4.91 | -5.14% |
| October 2026 | $3.41 | $4.06 | $4.99 | +0.46% |
| November 2026 | $3.40 | $4.08 | $5.05 | +0.42% |
| December 2026 | $3.26 | $3.92 | $4.90 | -3.86% |
Click any year to see its month-by-month INTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INTS price prediction for 2026 points to an average of $4.26 (low $3.62, high $4.90) — a potential gain of 0% on today's $4.26. A consolidation phase looks the most probable path here.
In 2027, INTS is projected to trade between $3.75 and $6.23, averaging $4.70 — a potential gain of +10% from today's $4.26. That is up +10% on the projected 2026 average. Price action looks broadly range-bound.
Intensity Therapeutics, Inc.'s 2028 outlook centres on $5.08, within a $3.93 to $6.99 range. That is up +8% on the projected 2027 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, INTS could reach as high as $7.05, with a base case around $4.97 and support toward $3.76 — roughly +17% from $4.26. Price action looks broadly range-bound.
Expect INTS to range from $3.51 to $6.89 through 2030. The $4.74 average target implies a +11% move from current prices. That is -5% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The INTS price prediction for 2031 points to an average of $4.63 (low $3.37, high $6.88) — a potential gain of +9% on today's $4.26. Price action looks broadly range-bound.
In 2032, INTS is projected to trade between $3.54 and $7.51, averaging $4.96 — a potential gain of +16% from today's $4.26. That is up +7% on the projected 2031 average. A consolidation phase looks the most probable path here.
Intensity Therapeutics, Inc.'s 2033 outlook centres on $5.47, within a $3.85 to $8.42 range. That is up +10% on the projected 2032 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2034, INTS could reach as high as $9.52, with a base case around $6.08 and support toward $4.21 — roughly +43% from $4.26. Buyers look set to stay in control over this stretch.
Expect INTS to range from $4.29 to $9.99 through 2035. The $6.29 average target implies a +48% move from current prices. That is up +3% on the projected 2034 average. Momentum favours further upside here.
The INTS price prediction for 2040 points to an average of $8.52 (low $5.44, high $14.41) — a potential gain of +100% on today's $4.26. Buyers look set to stay in control over this stretch.
In 2050, INTS is projected to trade between $6.21 and $20.26, averaging $10.94 — a potential gain of +157% from today's $4.26. That is up +28% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INTS today (≈ 234.741784 INTS) could be worth
$2,568.95
+$1,568.95 (+157%) by 2050 · US Dollar
Based on the average projected INTS price of $10.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INTSwould be worth at today's price.
$1,000 invested in INTS on Jul 31, 2025 (≈ 144.404328 INTS) would be worth
$615.16
-$384.84 (-38.5%) today · 0.62× · US Dollar
Based on a INTS entry price of $6.93 vs. today's $4.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.45 | $957.3 | -4.3% |
| 1 month ago | $4.15 | $1,026.51 | +2.7% |
| 3 months ago | $5.19 | $820.81 | -17.9% |
| 6 months ago | $9.18 | $464.31 | -53.6% |
| 1 year ago | $6.93 | $615.16 | -38.5% |
| All time (3.1y) ago | $149 | $28.59 | -97.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INTS forecast.
Our base-case forecast reaches $8.50 around 2040.
Implied market cap at $8.50: $22.97M
The multi-year forecast presents a gradual path higher from 2026 onward. The 2026 forecast shows a min of $3.62, an avg of $4.05, and a max of $4.64 with a neutral sentiment and 0% ROI. By 2033 the avg rises to $5.23 with a bullish stance and a 29.1% ROI, followed by further gains through 2034 ($5.78, 42.8%), 2035 ($5.97, 47.4%), and into 2040 where the avg is $8.11 and ROI reaches 100.2%.
By 2050 the avg is $10.36 with a 155.9% ROI and bullish sentiment. These figures illustrate substantial long‑term upside, tempered by near‑term volatility and risk. These are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
The 2030 forecast shows min $3.35, avg $4.53, max $6.59 with ROI 11.8% and sentiment NEUTRAL.
Short‑term sentiment is BEARISH. The long‑term forecast shows bullish momentum beginning around 2033, with the avg price rising to $5.23 in 2033, $8.11 by 2040, and $10.36 by 2050, with ROI up to 155.9%. These are estimates; they carry uncertainty and are not guarantees.
The 2050 forecast has an avg of $10.36 and a max of $19.20, with a 155.9% ROI, indicating the possibility of reaching the $10 level on average by 2050, supported by a bullish trajectory in later years.
The 30‑day range is $3.38 to $4.86, with a current price of $4.05.
Current price is $4.05, market cap is $10.95M, and rank is 4786.
Intensity Therapeutics, Inc. Community Discussion
0Share your Intensity Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.